The popular diabetes drug metformin reversed left ventricular hypertrophy (LVH) in a randomized trial of patients with coronary artery disease but without diabetes, suggesting a potential new use for the medication.

The FDA has cleared Gelesis100 hydrogel capsules to be used as a weight management aid alongside diet and exercise in adults with body mass indexes (BMIs) ranging from 25 to 40, according to an April 14 press release from the product’s manufacturer.

People diagnosed with type 2 diabetes at 40 or younger were about twice as likely to die over 5.6 years of follow-up compared to age-matched controls, according to a registry study from Sweden. But the relationship weakened substantially as the age of onset progressed, such that patients diagnosed in their 80s carried no excess mortality risk.

Medtronic has struck a value-based agreement with Blue Cross and Blue Shield of Minnesota in which the medical device company will pay back the insurer if patients using the Guardian Connect continuous glucose monitoring (CGM) system fail to keep their blood sugar levels within a specified range.

Rare protein-truncating variants in the apolipoprotein B (APOB) gene are linked to lower triglycerides and LDL cholesterol levels and also appear to be protective against coronary heart disease (CHD), according to a study published in Circulation: Genomic and Precision Medicine.

A meta-analysis of sham-controlled renal denervation trials published in the Journal of the American College of Cardiology found the catheter-based procedure was associated with statistically significant drops in ambulatory and office blood pressure measurements among hypertensive patients.

People who reported waking up in the middle of the night to use the bathroom were 40 percent more likely to have hypertension, according to a study presented March 30 at the Japanese Circulation Society’s annual scientific meeting.

The American Diabetes Association (ADA) issued updates to its 2019 Standards of Medical Care in Diabetes on March 27 in light of recent evidence surrounding icosapent ethyl and dapagliflozin.